Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Gliosarcoma: Neuroimaging and Immunohistochemical Findings.

Peckham ME, Osborn AG, Palmer CA, Tsai A, Salzman KL.

J Neuroimaging. 2019 Jan;29(1):126-132. doi: 10.1111/jon.12565. Epub 2018 Oct 8.

PMID:
30295979
2.

Clinicopathologic and genomic features of gliosarcomas.

Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH.

J Neurooncol. 2012 May;107(3):643-50. doi: 10.1007/s11060-011-0790-3. Epub 2012 Jan 20.

PMID:
22270848
3.

Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.

Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF.

J Neurooncol. 2015 Nov;125(2):401-10. doi: 10.1007/s11060-015-1930-y. Epub 2015 Sep 9.

PMID:
26354773
4.

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K.

Acta Neuropathol Commun. 2016 Aug 8;4(1):79. doi: 10.1186/s40478-016-0351-2.

5.

Case comparison and literature review of glioblastoma: A tale of two tumors.

Mendez G, Ozpinar A, Raskin J, Gultekin SH, Ross DA.

Surg Neurol Int. 2014 Aug 2;5:121. doi: 10.4103/2152-7806.138034. eCollection 2014. Review.

6.

Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.

Akyerli CB, Yüksel Ş, Can Ö, Erson-Omay EZ, Oktay Y, Coşgun E, Ülgen E, Erdemgil Y, Sav A, von Deimling A, Günel M, Yakıcıer MC, Pamir MN, Özduman K.

J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.

PMID:
28621624
7.
8.

Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.

Houdova Megova M, Drábek J, Dwight Z, Trojanec R, Koudeláková V, Vrbková J, Kalita O, Mlcochova S, Rabcanova M, Hajdúch M.

Klin Onkol. 2017 Fall;30(5):361-371. doi: 10.14735/amko2017361.

PMID:
29031038
9.

Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.

Macaulay RJ.

Cancer Control. 2015 Apr;22(2):200-5. Review.

PMID:
26068765
10.

An IDH1-mutated primary gliosarcoma: case report.

Hsieh JK, Hong CS, Manjila S, Cohen ML, Lo S, Rogers L, Sloan AE.

J Neurosurg. 2017 Feb;126(2):476-480. doi: 10.3171/2016.2.JNS151482. Epub 2016 May 6.

PMID:
27153165
11.

DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.

Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H.

Acta Neuropathol Commun. 2015 Jun 20;3:34. doi: 10.1186/s40478-015-0213-3.

12.

Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Pratt D, Pittaluga S, Palisoc M, Fetsch P, Xi L, Raffeld M, Gilbert MR, Quezado M.

J Neuropathol Exp Neurol. 2017 Aug 1;76(8):697-708. doi: 10.1093/jnen/nlx051.

13.

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.

Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O, Paterra R, Marie Y, Finocchiaro G, Sanson M.

Neurology. 2014 Sep 23;83(13):1200-6. doi: 10.1212/WNL.0000000000000814. Epub 2014 Aug 22.

PMID:
25150284
14.

Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.

Sartori E, Langer R, Vassella E, Hewer E, Schucht P, Zlobec I, Berezowska S.

Oncol Rep. 2017 Oct;38(4):2394-2400. doi: 10.3892/or.2017.5863. Epub 2017 Aug 1.

PMID:
28765916
15.

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.

SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y.

Cancer Sci. 2012 Feb;103(2):269-73. doi: 10.1111/j.1349-7006.2011.02134.x. Epub 2011 Nov 28.

16.

Immunohistochemical classification of primary and secondary glioblastomas.

Lee KS, Choe G, Nam KH, Seo AN, Yun S, Kim KJ, Cho HJ, Park SH.

Korean J Pathol. 2013 Dec;47(6):541-8. doi: 10.4132/KoreanJPathol.2013.47.6.541. Epub 2013 Dec 24.

17.

Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.

Smith DR, Wu CC, Saadatmand HJ, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, Wang SH, Canoll P, McKhann GM 2nd, Wang TJC.

J Neurooncol. 2018 Apr;137(2):303-311. doi: 10.1007/s11060-017-2718-z. Epub 2017 Dec 20.

PMID:
29264835
18.
19.

Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).

Leibetseder A, Ackerl M, Flechl B, Wöhrer A, Widhalm G, Dieckmann K, Kreinecker SS, Pichler J, Hainfellner J, Preusser M, Marosi C.

Neuro Oncol. 2013 Jan;15(1):112-21. doi: 10.1093/neuonc/nos283. Epub 2012 Dec 7.

20.

[Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].

Pan Y, Qi XL, Wang LM, Dong RF, Zhang M, Zheng DF, Chang Q, Zhong YF.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):292-8. doi: 10.3760/cma.j.issn.0529-5807.2013.05.002. Chinese.

PMID:
24004584

Supplemental Content

Support Center